PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Clinical trials for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNE THROMBOCYTOPENIA (ITP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for ITP patients: experimental drug aims to keep platelets stable
Disease control OngoingThis study tests an experimental drug called ianalumab in adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding. Participants receive ianalumab or a placebo alongside standard steroid treatment. The goal is to …
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 11:49 UTC
-
New hope for ITP patients: experimental drug aims to boost platelet counts
Disease control OngoingThis study tests an experimental drug called ianalumab in 41 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risks. Participants have already tried steroids and another drug (TPO-RA) without lasting succe…
Matched conditions: PRIMARY IMMUNE THROMBOCYTOPENIA (ITP)
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 17, 2026 11:34 UTC